WHEN TO SWITCH VERSUS AUGMENT PHARMACOTHERAPIES

Determining when to switch versus augment pharmacotherapy is a central challenge in the treatment of psychiatric disorders, including major depressive disorder. Clinicians must balance symptom severity, treatment history, side-effect burden, and functional impairment while navigating an expanding evidence base and evolving clinical guidelines. Switching may be preferred when patients experience intolerable adverse effects, lack of response or only partial response, and clear mechanistic mismatch with the underlying disorder. Augmentation strategies can be highly effective when partial but inadequate improvement is observed, or continuation of background treatment is clinically indicated. The decision is further influenced by comorbidities, patient preferences, pharmacokinetic considerations, and the risk-benefit profile of potential adjunctive agents. Understanding the nuances that guide switching versus augmentation is therefore essential for optimizing outcomes across major psychiatric disorders and their complex presentations. This presentation will also focus on shared decision-making approaches that can be utilized to make the decision of switch versus augment.

References

Papakostas GI, Trivedi MH, Shelton RC, Iosifescu DV, Thase ME, Jha MK, Mathew SJ, DeBattista C, Dokucu ME, Brawman-Mintzer O, Currier GW, McCall WV, Modirrousta M, Macaluso M, Bystritsky A, Rodriguez FV, Nelson EB, Yeung AS, Feeney A, MacGregor LC, Carmody T, Fava M. Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial. Mol Psychiatry. 2024 Aug;29(8):22872295. Lenze EJ, Mulsant BH, Roose SP, Lavretsky H, Reynolds CF 3rd, Blumberger DM, Brown PJ, Cristancho P, Flint AJ, Gebara MA, Gettinger TR, Lenard E, Miller JP, Nicol GE, Oughli HA, Pham VT, Rollman BL, Yang L, Karp JF. Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression. N Engl J Med. 2023 Mar 23;388(12):10671079.